ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2068

Integration of Basic Science into Virtual Patient Cases to Enhance Clinical Reasoning Skills

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1783

Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis

(1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1875

Inter and Intra-observer Reliability of Assessment for Nailfold Capillary Abnormalities in Rheumatic Patients with Raynaud’s Phenomenon

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2297

Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2078

Interim Evaluation of a 6 Year Remote Online Adaptive Learning Platform Module for Rheumatology Fellows: Applied Rheumatology on the Go

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 2212

Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2035

Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2042

Intraocular Cytokine Profiling of Autoimmune Uveitis

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 1914

Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: 1966

Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

9:00AM-11:00AM: Abstract Number: 2369

Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients

(2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

9:00AM-11:00AM: Abstract Number: 1826

Investigating the Health Profiles and the Prevalence and Correlates of Cannabis Use Among Patients Accessing Rheumatologic Care in Alberta, Canada

(1796–1826) Epidemiology & Public Health Poster III

9:00AM-11:00AM: Abstract Number: 2031

Involving Patients Research Partners in Research in Rheumatology: Where Do We Stand? A Scoping Review of Recent Randomized Controlled Trials and Translational Science Studies

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2242

Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 1865

Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative

(1862–1894) Imaging of Rheumatic Diseases Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].